Comprehensive bioinformatics analysis of the E2F family in human clear cell renal cell carcinoma

Liu,Zhi-Guo; Su,Jing; Liu,Hao; Yang,Xue-Jian; Yang,Xue; Wei,Ye; Zhu,Xin-Yao; Song,Yong; Zhao,Xian-Cheng; Guo,Hong-Lin

doi:10.3892/ol.2022.13471

Comprehensive bioinformatics analysis of the E2F family in human clear cell renal cell carcinoma

Authors:
- Zhi-Guo Liu
- Jing Su
- Hao Liu
- Xue-Jian Yang
- Xue Yang
- Ye Wei
- Xin-Yao Zhu
- Yong Song
- Xian-Cheng Zhao
- Hong-Lin Guo
View Affiliations

Affiliations: Department of Hospital Pharmacy, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu 223800, P.R. China, Department of Hematology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu 223800, P.R. China, Department of Urinary Surgery, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu 223800, P.R. China, Department of Cardiology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu 223800, P.R. China, First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China, Institute of Preventive Medicine Information, Inspection and Protection, Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei 430070, P.R. China, School of Public Administration, South Central University for Nationalities, Wuhan, Hubei 430074, P.R. China
Published online on: August 19, 2022 https://doi.org/10.3892/ol.2022.13471
Article Number: 351
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clear cell renal cell carcinoma (ccRCC) originates from renal tubular epithelial cells and is the most common pathological renal cell carcinoma type with the worst prognosis. The relationship between the expression, prognosis and mechanism of ccRCC and the E2F family remains challenging. In the present study, RNA sequencing and clinical data of ccRCC from The Cancer Genome Atlas and two datasets, GSE36895 and GSE53757, from the Gene Expression Omnibus were used to identify the role of the E2F family in ccRCC. A total of 10 groups of tumor tissues and paired‑normal tissues from patients with ccRCC were verified by reverse transcription‑quantitative PCR. the expression, tumor grade and stage, prognosis and regulatory mechanism of the E2F family in ccRCC were analyzed. It was found that the expression levels of E2F1 to 4 and 6 to 8 were higher in ccRCC tissues than in normal tissues, whereas the expression level of E2F5 was lower in the former than in the latter. The expression levels of E2F1 to 8 were correlated with tumor stage and grade. Low expression of E2F1 to 5 and 7 to 8 was significantly associated with longer overall survival, disease‑specific survival and progression‑free survival times. The data revealed that the E2F family rarely has genetic mutations. The expression of E2F1, E2F2, E2F5, E2F7 and E2F8 was significantly correlated with DNA methylation, and E2F1 to E2F7 were significantly correlated with copy number and the data showed that the expression of E2Fs was significantly correlated with the cell cycle. The results of the present study suggested that E2F family genes may be potential targets for ccRCC molecular diagnosis and targeted therapy.

View Figures

View References

1	Gray RE and Harris GT: Renal cell carcinoma: Diagnosis and management. Am Fam Physician. 99:179–184. 2019.PubMed/NCBI
2	Linehan WM and Ricketts CJ: The cancer genome atlas of renal cell carcinoma: Findings and clinical implications. Nat Rev Urol. 16:539–552. 2019. View Article : Google Scholar : PubMed/NCBI
3	Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG and Kolenko VM: Resistance to systemic therapies in clear cell renal cell carcinoma: Mechanisms and management strategies. Mol Cancer Ther. 17:1355–1364. 2018. View Article : Google Scholar : PubMed/NCBI
4	Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F, Castellano G, Bettocchi C, Ditonno P and Battaglia M: Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 19:397–407. 2019. View Article : Google Scholar : PubMed/NCBI
5	Tegos T, Tegos K, Dimitriadou A and Dimitriadis G: Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma. J BUON. 24:1340–1353. 2019.PubMed/NCBI
6	Schodel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P and Mole DR: Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 69:646–657. 2016. View Article : Google Scholar : PubMed/NCBI
7	Wang H, Wang X, Xu L, Zhang J and Cao H: Integrated analysis of the E2F transcription factors across cancer types. Oncol Rep. 43:1133–1146. 2020.PubMed/NCBI
8	Pennycook BR, Vesela E, Peripolli S, Singh T, Barr AR, Bertoli C and de Bruin RAM: E2F-dependent transcription determines replication capacity and S phase length. Nat Commun. 11:35032020. View Article : Google Scholar : PubMed/NCBI
9	Kovesdi I, Reichel R and Nevins JR: Role of an adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control. Proc Natl Acad Sci USA. 84:2180–2184. 1987. View Article : Google Scholar : PubMed/NCBI
10	Ertosun MG, Hapil FZ and Nidai OO: E2F1 transcription factor and its impact on growth factor and cytokine signaling. Cytokine Growth Factor Rev. 31:17–25. 2016. View Article : Google Scholar : PubMed/NCBI
11	Kent LN and Leone G: The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 19:326–338. 2019. View Article : Google Scholar : PubMed/NCBI
12	Zheng L, Dou X, Song H, Gao R and Tang X: TRPV1 acts as a tumor suppressor and is associated with immune cell infiltration in clear cell renal cell carcinoma: Evidence from integrated analysis. J Cancer. 11:5678–5688. 2020. View Article : Google Scholar : PubMed/NCBI
13	Kang W, Zhang M, Wang Q, Gu D, Huang Z, Wang H, Xiang Y, Xia Q, Cui Z and Jin X: The SLC family are candidate diagnostic and prognostic biomarkers in clear cell renal cell carcinoma. Biomed Res Int. 2020:19329482020. View Article : Google Scholar : PubMed/NCBI
14	Zheng Y, Fang YC and Li J: PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 18:5399–5407. 2019.PubMed/NCBI
15	Wang H, Yan C and Ye H: Overexpression of MUC16 predicts favourable prognosis in MUC16-mutant cervical cancer related to immune response. Exp Ther Med. 20:1725–1733. 2020. View Article : Google Scholar : PubMed/NCBI
16	Martinez-Saez O, Borau PG, Alonso-Gordoa T, Molina-Cerrillo J and Grande E: Targeting HIF-2 alpha in clear cell renal cell carcinoma: A promising therapeutic strategy. Crit Rev Oncol Hematol. 111:117–123. 2017. View Article : Google Scholar : PubMed/NCBI
17	Attwooll C, Denchi EL and Helin K: The E2F family: Specific functions and overlapping interests. EMBO J. 23:4709–4716. 2004. View Article : Google Scholar : PubMed/NCBI
18	Sun CC, Li SJ, Hu W, Zhang J, Zhou Q, Liu C, Li LL, Songyang YY, Zhang F, Chen ZL, et al: Comprehensive analysis of the expression and prognosis for E2Fs in human breast cancer. Mol Ther. 27:1153–1165. 2019. View Article : Google Scholar : PubMed/NCBI
19	Jiao Y, Li Y, Fu Z, Hou L, Chen Q, Cai Y, Jiang P, He M and Yang Z: OGDHL expression as a prognostic biomarker for liver cancer patients. Dis Markers. 2019:90371312019. View Article : Google Scholar : PubMed/NCBI
20	Wei WY, Yan LH, Wang XT, Li L, Cao WL, Zhang XS, Zhan ZX, Yu H, Xie YB and Xiao Q: E2F-1 overexpression inhibits human gastric cancer MGC-803 cell growth in vivo. World J Gastroenterol. 21:491–501. 2015. View Article : Google Scholar : PubMed/NCBI
21	Fang Z, Lin M, Li C, Liu H and Gong C: A comprehensive review of the roles of E2F1 in colon cancer. Am J Cancer Res. 10:757–768. 2020.PubMed/NCBI
22	Yin H, Lowery M and Glass J: In prostate cancer C/EBPalpha promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT. Prostate. 69:1001–1016. 2009. View Article : Google Scholar : PubMed/NCBI
23	Fang DZ, Wang YP, Liu J, Hui XB, Wang XD, Chen X and Liu D: MicroRNA-129-3p suppresses tumor growth by targeting E2F5 in glioblastoma. Eur Rev Med Pharmacol Sci. 22:1044–1050. 2018.PubMed/NCBI
24	Li SL, Sui Y, Sun J, Jiang TQ and Dong G: Identification of tumor suppressive role of microRNA-132 and its target gene in tumorigenesis of prostate cancer. Int J Mol Med. 41:2429–2433. 2018.PubMed/NCBI
25	Xu H, Fei D, Zong S and Fan Z: MicroRNA-154 inhibits growth and invasion of breast cancer cells through targeting E2F5. Am J Transl Res. 8:2620–2630. 2016.PubMed/NCBI
26	Lafta IJ: E2F6 is essential for cell viability in breast cancer cells during replication stress. Turk J Biol. 43:293–304. 2019. View Article : Google Scholar : PubMed/NCBI
27	Moreno E, Toussaint MJM, van Essen SC, Bongiovanni L, van Liere EA, Koster MH, Yuan R, van Deursen JM, Westendorp B and de Bruin A: E2F7 is a potent inhibitor of liver tumor growth in adult mice. Hepatology. 73:303–317. 2021. View Article : Google Scholar : PubMed/NCBI
28	Kent LN, Rakijas JB, Pandit SK, Westendorp B, Chen HZ, Huntington JT, Tang X, Bae S, Srivastava A, Senapati S, et al: E2f8 mediates tumor suppression in postnatal liver development. J Clin Invest. 126:2955–2969. 2016. View Article : Google Scholar : PubMed/NCBI
29	Guo L, Jones MC, Liu Y, Yv S, Zhu Y and Guo Y: Cross-cultural validation of the student nurse stress index scale: A descriptive survey targeting student nurses in China. J Affect Disord. 251:31–38. 2019. View Article : Google Scholar : PubMed/NCBI
30	Klutstein M, Nejman D, Greenfield R and Cedar H: DNA methylation in cancer and aging. Cancer Res. 76:3446–3450. 2016. View Article : Google Scholar : PubMed/NCBI